X4 Pharmaceuticals Inc represents a strong commitment to transforming the lives of patients through innovative therapies. With a focus on rare diseases and severe genetic disorders, the company aims to develop and commercialize treatments that address significant unmet medical needs. X4 Pharmaceuticals is driven by a core philosophy of scientific excellence, collaboration, and patient-centricity. By employing novel approaches and leveraging cutting-edge research, the company strives to deliver groundbreaking solutions that improve the quality of life for individuals facing challenging health conditions. With a strong emphasis on research and development, X4 Pharmaceuticals continues to pioneer advancements in the field of biotechnology.

X4 Pharmaceuticals Inc is primarily present in the United States.

X4 Pharmaceuticals Inc has achieved several significant milestones since its inception. Notably, the company successfully completed its initial public offering (IPO) in 2018, indicating investor confidence in its potential. Moreover, X4 Pharmaceuticals has made remarkable progress in the development of its lead candidate, X4P-001, for the treatment of various rare diseases. The company has initiated multiple clinical trials, showing promising results in the improvement of patients' condition. Additionally, X4 Pharmaceuticals has established strategic partnerships with renowned organizations to bolster research and development efforts further. These achievements highlight the commitment and expertise of X4 Pharmaceuticals Inc in advancing innovative therapies that address unmet medical needs.

X4 Pharmaceuticals Inc is a leading biopharmaceutical company focused on developing innovative therapies for rare diseases and cancer. Founded in 2015, X4 Pharmaceuticals has quickly gained recognition for its novel approach to targeting the body's immune system and restoring its natural ability to fight diseases. The company's groundbreaking research and development efforts center around developing small molecule drugs that selectively modulate chemokine receptors, controlling cellular migration and activation. With a diverse pipeline of potential therapies, X4 Pharmaceuticals is committed to delivering breakthrough treatments and improving the lives of patients worldwide.

The main competitors of X4 Pharmaceuticals Inc in the market include companies such as Company A, Company B, and Company C. These companies compete with X4 Pharmaceuticals Inc in terms of developing and commercializing innovative pharmaceutical products. With its unique approach and strong product pipeline, X4 Pharmaceuticals Inc aims to differentiate itself and capture a significant market share in the pharmaceutical industry. However, the competitive landscape remains dynamic, and market conditions may change over time.

X4 Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

X4 Pharmaceuticals Inc operates under a business model focused on developing targeted therapies for rare genetic diseases and cancer. By leveraging its proprietary platform, X4P-001, the company aims to address serious unmet medical needs and improve patients' lives. X4 Pharmaceuticals Inc's innovative approach targets chemokine receptors to modulate the immune system and restore normal cellular function. With a mission to bring transformative advancements in precision medicine, X4 Pharmaceuticals Inc is committed to advancing its pipeline of promising drug candidates through rigorous research, clinical development, and strategic partnerships.

Raportul X4 Pharmaceuticals preț/beneficiu este -3,47.

Raportul X4 Pharmaceuticals preț/vânzări este 19,58.

Scorul de calitate AlleAktien pentru X4 Pharmaceuticals este 2/10.

Cifra de afaceri a așteptată X4 Pharmaceuticals este de 6,45 milioane USD.

Profitul așteptată X4 Pharmaceuticals este -36,34 milioane USD.

The X4 Pharmaceuticals Inc is a publicly traded biotechnology company from the USA that develops innovative therapies for rare diseases. The company is known for its groundbreaking research program in the field of immuno-oncology, inflammatory diseases, and primary immunodeficiencies. The X4 Pharmaceuticals Inc business model is based on the discovery, development, and commercialization of new drugs developed using new technologies. The company conducts research and development in collaboration with top academic institutions and independent laboratories. The company has various divisions, including research and development, production, and marketing. X4 Pharmaceuticals Inc focuses on the development of drugs targeting CXCR4 receptors. These are proteins responsible for controlling signals within the immune system. The company has developed several products, including X4P-001, a novel antibody therapeutic for cancer patients. X4P-001 targets CXCR4, a receptor that is overexpressed in many types of cancer and is considered responsible for disease progression. Another product that the company has developed is X4P-002. This medication is nearing clinical trials and is used for the treatment of primary immunodeficiencies and inflammatory diseases. X4P-002 has been recognized for its outstanding efficacy and tolerability in animal models. In addition to these products, X4 Pharmaceuticals Inc also has a comprehensive portfolio of patents to secure its technologies and products. The company has filed hundreds of patent applications for its drug candidates as well as its scientific research. X4 Pharmaceuticals Inc also operates production and business development units dedicated to reaching potential partners and investors for its technologies and drug candidates. By partnering with other pharmaceutical companies and scientific institutions, the company can expand and accelerate its product pipeline. Overall, the X4 Pharmaceuticals Inc business model is based on the discovery and development of new therapies for rare diseases through the exploration of novel technologies. The company aims to bring innovative and effective products to the market that can improve the lives of patients worldwide. With a dedicated and experienced leadership team and a team of experts in the field of biotechnology and medicine, X4 Pharmaceuticals Inc is on track to become one of the leading companies in the development of new drugs.

X4 Pharmaceuticals distribuie un dividend de 0 USD în plăți anuale.

Dividenda nu poate fi calculată în prezent pentru X4 Pharmaceuticals sau compania nu distribuie dividende.

Codul ISIN pentru X4 Pharmaceuticals este US98420X1037.

Codul WKN al X4 Pharmaceuticals este A2PFVY.

Ticker-ul pentru X4 Pharmaceuticals este XFOR.

În ultimele 12 luni, X4 Pharmaceuticals a plătit un dividend în valoare de . Aceasta corespunde unei randamente a dividendului de aproximativ . Pentru următoarele 12 luni, X4 Pharmaceuticals va plăti probabil un dividend de 0 USD.

Randamentul dividendelor pentru X4 Pharmaceuticals este în prezent de .

X4 Pharmaceuticals plătește un dividend trimestrial. Acesta este distribuit în lunile .

X4 Pharmaceuticals a plătit dividende în fiecare an, în ultimii 0 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 0 USD. Acest lucru corespunde unei randamente a dividendelor de 0 %.

X4 Pharmaceuticals este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de X4 Pharmaceuticals de la 16.09.2024 în valoare de 0 USD, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 16.09.2024.

Ultima plată a dividendului a fost efectuată la 16.09.2024.

În anul 2023, X4 Pharmaceuticals a distribuit 0 USD sub formă de dividende.

Dividendele de la X4 Pharmaceuticals sunt distribuite în USD.